CellOrigin Biotech

CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has signed a global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” chimeric antigen receptor macrophages (CAR-iMACs) for cancer immunotherapy. Financial terms of the agreement were not disclosed. Strategic Partnership and R&D SynergiesThe partnership combines CellOrigin’s expertise…